AU2013349682A1 - Composition for immediate and extended release - Google Patents

Composition for immediate and extended release Download PDF

Info

Publication number
AU2013349682A1
AU2013349682A1 AU2013349682A AU2013349682A AU2013349682A1 AU 2013349682 A1 AU2013349682 A1 AU 2013349682A1 AU 2013349682 A AU2013349682 A AU 2013349682A AU 2013349682 A AU2013349682 A AU 2013349682A AU 2013349682 A1 AU2013349682 A1 AU 2013349682A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
tolterodine
active ingredient
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013349682A
Other languages
English (en)
Inventor
Varinder Ahuja
Umesh Vinayakrao Barabde
Rambabu BOORUGU
Arne HAGSTEN
Amol Vilasrao SOMWANSHI
Rajan Verma
Kristin Wannerberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Publication of AU2013349682A1 publication Critical patent/AU2013349682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013349682A 2012-11-21 2013-11-21 Composition for immediate and extended release Abandoned AU2013349682A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN3575/DEL/2012 2012-11-21
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20
IN3947/DEL/2012 2012-12-20
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (1)

Publication Number Publication Date
AU2013349682A1 true AU2013349682A1 (en) 2015-06-04

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013349682A Abandoned AU2013349682A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Country Status (18)

Country Link
EP (1) EP2922525A1 (OSRAM)
JP (1) JP2016500088A (OSRAM)
KR (1) KR20150085826A (OSRAM)
CN (1) CN104797240A (OSRAM)
AR (1) AR093585A1 (OSRAM)
AU (1) AU2013349682A1 (OSRAM)
BR (1) BR112015011430A2 (OSRAM)
CA (1) CA2891365A1 (OSRAM)
EA (1) EA201590805A1 (OSRAM)
HK (1) HK1213779A1 (OSRAM)
IL (1) IL238648A0 (OSRAM)
IN (1) IN2015DN03984A (OSRAM)
MX (1) MX2015006399A (OSRAM)
PH (1) PH12015501096A1 (OSRAM)
SG (2) SG10201703388TA (OSRAM)
TW (1) TW201422254A (OSRAM)
WO (1) WO2014079922A1 (OSRAM)
ZA (1) ZA201503603B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
CN106999538A (zh) * 2014-11-20 2017-08-01 阿勒根公司 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物
EP3244881A4 (en) 2015-01-12 2018-08-15 Nano Pharmaceutical Laboratories LLC Layered sustained-release microbeads and methods of making the same
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2018111400A (ru) * 2015-09-01 2019-10-03 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Препарат пролонгированного, отсроченного и немедленного высвобождения, способ его получения и применения
EP3355864A4 (en) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
EP3355877A4 (en) * 2015-09-30 2019-05-15 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
EP3389661A4 (en) * 2015-12-18 2019-12-18 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING THE FREQUENCY OF URINATION, METHOD FOR THE PRODUCTION AND USE THEREOF
JP7158284B2 (ja) 2016-04-21 2022-10-21 ヴァルキュリア アクチアボラグ がんを前処置するための組成物および方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7042275B2 (ja) * 2017-01-11 2022-03-25 フェリング・ベー・フェー 速崩壊性医薬組成物
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
US12389928B1 (en) * 2024-10-25 2025-08-19 Mccormick & Company, Inc. Flavor-changing product

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4052997A (en) 1996-07-19 1998-02-10 Clarke-Garegg, Margaret A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
DE60307082D1 (de) * 2002-05-07 2006-09-07 Ferring Bv In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 一种口腔速溶制剂及其生产方法
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
CN102245171A (zh) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 缓释微粒及其制备方法
CA2769760A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
ES2643087T3 (es) 2010-03-29 2017-11-21 Ferring B.V. Composición farmacéutica de disolución rápida
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
MX356601B (es) * 2010-03-30 2018-05-29 Productos Maver S A De C V Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
IN2015DN03984A (OSRAM) 2015-10-02
SG10201703388TA (en) 2017-05-30
BR112015011430A2 (pt) 2017-07-11
IL238648A0 (en) 2015-06-30
HK1213779A1 (zh) 2016-07-15
PH12015501096A1 (en) 2015-07-27
CN104797240A (zh) 2015-07-22
WO2014079922A1 (en) 2014-05-30
SG11201503913TA (en) 2015-06-29
JP2016500088A (ja) 2016-01-07
EA201590805A1 (ru) 2015-11-30
AR093585A1 (es) 2015-06-10
MX2015006399A (es) 2015-07-21
ZA201503603B (en) 2016-01-27
EP2922525A1 (en) 2015-09-30
TW201422254A (zh) 2014-06-16
KR20150085826A (ko) 2015-07-24
CA2891365A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
AU2013349682A1 (en) Composition for immediate and extended release
US20150306170A1 (en) Composition for immediate and extended release
US10512695B2 (en) Fast dissolving pharmaceutical composition
US9731018B2 (en) Fast dissolving pharmaceutical composition
US10023335B2 (en) Fast dissolving pharmaceutical composition
US10952959B2 (en) Fast disintegrating pharmaceutical composition
HK1181649B (en) A fast dissolving pharmaceutical composition

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted